![Mark Rubinstein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 258 588 $ au 30/06/2026
Mark L.
Rubinstein is Chief Medical Officer at Achieve Life Sciences, Inc. starting in 2025.
Formerly, Dr. Rubinstein was Head-Medical Affairs at Blip Products, Inc. Education includes a doctorate from Yale University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/01/2026 | 39 600 ( 0,04 % ) | 258 588 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. | Directeur Technique/Scientifique/R&D | 01/10/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
Blip Products, Inc.
 Blip Products, Inc. Pharmaceuticals: MajorHealth Technology Produces and sells nicotine replacement therapy products through online | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 3 |
|---|---|
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Achieve Life Sciences, Inc.
 Achieve Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes cytisinicline for smoking cessation and nicotine addiction | Health Technology |
Blip Products, Inc.
Blip Products, Inc. Pharmaceuticals: MajorHealth Technology Produces and sells nicotine replacement therapy products through online | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
